Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan

You may also be interested in...



Daiichi Sankyo Adds To Japan's Biosimilar Fray In Two-compound Deal

Daiichi Sankyo is teaming with virtual startup Coherus BioSciences for etanercept and rituximab.

Korea’s Celltrion Prepares Remicade Biosimilar Application For KFDA

Korea’s biosimilar frontrunner Celltrion is only one step away from the actual sales of its first biosimilar as it gears up to file for KFDA approval in February for its biosimilar of Johnson & Johnson’s rheumatoid arthritis agent Remicade.

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Tags:
Latest Headlines

BMS Has A Strong Pipeline, But Access Challenges Remain

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

Takeda, Astellas Found New JV To Support Japanese Bioventures

Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal

See All
UsernamePublicRestriction

Register

SC073605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By